These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11414163)

  • 41. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M; Richard H; Pilote L
    BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable].
    Simon B
    MMW Fortschr Med; 2001 May; 143(18):51-2. PubMed ID: 11387712
    [No Abstract]   [Full Text] [Related]  

  • 43. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 44. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM; Lévesque LE; Zhang B
    Heart; 2007 Feb; 93(2):189-94. PubMed ID: 16849374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prescribing patterns of rofecoxib in the primary care setting: results of a French survey].
    Bannwarth B; Logeart I; Vergult G
    Rev Med Interne; 2004 Oct; 25(10):710-4. PubMed ID: 15471596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
    Laine L; Maller ES; Yu C; Quan H; Simon T
    Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Celecoxib and the CLASS study--a statement].
    Wibe E; Maehlum S
    Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2218. PubMed ID: 12426902
    [No Abstract]   [Full Text] [Related]  

  • 49. [What do we know about the cardiovascular toxicity of the NSAIDs?].
    Sibilia J; Deray G; Montalescot G
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Rofecoxib, a new NSAID preparation with selective COX-2 inhibition].
    Pødenphant J
    Ugeskr Laeger; 2000 Sep; 162(39):5233-6. PubMed ID: 11043057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Celecoxib, rofecoxib, and acute temporary visual impairment.
    Coulter DM; Clark DW; Savage RL
    BMJ; 2003 Nov; 327(7425):1214-5. PubMed ID: 14630760
    [No Abstract]   [Full Text] [Related]  

  • 52. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
    Geis GS
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
    [No Abstract]   [Full Text] [Related]  

  • 53. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM; Mosholder AD; Lu S
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Swaak AJ; Theunissen DJ
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1476-7; author reply 1477-8. PubMed ID: 11503322
    [No Abstract]   [Full Text] [Related]  

  • 55. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
    Schneeweiss S; Glynn RJ; Avorn J; Mamdani M; Mogun H; Solomon DH
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1134-42. PubMed ID: 19844943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R; Ruzicka T; Grewe M
    Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
    Lanas A; García-Rodríguez LA; Arroyo MT; Gomollón F; Feu F; González-Pérez A; Zapata E; Bástida G; Rodrigo L; Santolaria S; Güell M; de Argila CM; Quintero E; Borda F; Piqué JM;
    Gut; 2006 Dec; 55(12):1731-8. PubMed ID: 16687434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
    Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI].
    Lems WF; Kuipers EJ
    Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.